1414367-81-9

Upstream product

• 1414367-80-8 C₂₇H₃₇NO₂Si 
• 1354035-49-6 methyl 4-bromo-1-(bromomethyl)-2-naphthoate 
• 1414367-68-2 5-bromo-2-[(1S,2S)-2-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one 
• 1354035-48-5 methyl 4-bromo-1-methyl-2-naphthoate 
• 73721-17-2 methyl 1-methyl-2-naphthoate 
• 1354035-50-9 5-bromo-2-[(1S, 2S)-2-hydroxycyclohexyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one 

Downstream Products

• 1414367-74-0 1-({2-[(1S,2S)-2-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl]-1-methyl-3-oxo-2,3-dihydro-1H-benzo[e]isoindol-5-yl}methyl)-4-(pyridin-2-yl)piperidine-4-carbonitrile 
• 1414365-99-3 1-({2-[(1S,2S)-2-hydroxycyclohexyl]-1-methyl-3-oxo-2,3-dihydro-1H-benzo[e]isoindol-5-yl}methyl)-4-(pyridine-2-yl)piperidine-4-carbonitrile 

Relevant academic research and scientific papers

Discovery of naphthyl-fused 5-membered lactams as a new class of M 1 positive allosteric modulators

Selective activation of the M1 muscarinic receptor via positive allosteric modulation represents an original approach to treat the cognitive decline in patients with Alzheimer's disease. A series of naphthyl-fused 5-membered lactams were identified as a new class of M1 positive allosteric modulators and were found to possess good potency and in vivo efficacy.